Cassava Biosciences(SAVA) – The biotechnology company said claims posted online late yesterday challenging its scientific integrity are false and misleading. The issue revolved around study data for an Alzheimer’s disease treatment. Cassava released a statement refuting each of 15 claims that the company calls “fiction.” Cassava tumbled 22.6% in the premarket.
免责声明:上述内容仅代表发帖人个人观点,不构成本平台的任何投资建议。
3
举报
登录后可参与评论
暂无评论